- Leukemia
- Liver Cancer
- Lung Cancer
- Lung Cancer – Non-Small Cell
- Lung Cancer – Small Cell
- Lymphoma
- Melanoma
- Mesothelioma
- Miscellaneous
- Multiple Myeloma
- Myelodysplastic Syndrome
- Neuroblastoma
- Non-Hodgkin’s Lymphoma
- Aggressive/Intermediate Grade Non-Hodgkin’s Lymphoma
- Follicular Lymphoma
- Highly Aggressive/High Grade Non-Hodgkin’s Lymphoma
- Indolent/Low Grade Non-Hodgkin’s Lymphoma
- Mantle Cell Non-Hodgkin’s Lymphoma
- Recurrent Non-Hodgkin’s Lymphoma
- Screening/Prevention Non-Hodgkin’s Lymphoma
- T-Cell Non-Hodgkin’s Lymphoma
- Osteosarcoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Rectal Cancer
- Renal Cancer
- Retinoblastoma
- Sarcoma
- Skin Cancer
- Supportive Care
- Management and Prevention of Anemia Supportive Care
- Management and Prevention of Anorexia and Weight Loss Supportive Care
- Management and Prevention of Bone Complications Supportive Care
- Management and Prevention of Fatigue Supportive Care
- Management and Prevention of Mucositis Supportive Care
- Management and Prevention of Nausea and Vomiting Supportive Care
- Management and Prevention of Neutropenia Supportive Care
- Management and Prevention of Thrombocytopenia Supportive Care
- Testicular Cancer
- Throat Cancer
- Thyroid Cancer
- Uterine Cancer
- Vaginal Cancer
Cancer News
Xtandi® Improves Survival in Advanced Prostate Cancer
(02/22/2016)
The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently published as rapid communication in the Journal of Clinical Oncology. Prostate cancer is the most frequently diagnosed cancer in men … Continue reading "Xtandi® Improves Survival in Advanced Prostate Cancer"